FOLD Amicus Therapeutics, Inc. Stock Quote

FOLD [NASD]

Index	-	P/E	-	EPS (ttm)	-1.15	Insider Own	1.00%	Shs Outstand	259.16M	Perf Week	-6.61%
Market Cap	2.83B	Forward P/E	-	EPS next Y	-0.81	Insider Trans	-19.75%	Shs Float	234.32M	Perf Month	-40.93%
Income	-295.20M	PEG	-	EPS next Q	-0.23	Inst Own	-	Short Float	13.27%	Perf Quarter	-51.94%
Sales	245.60M	P/S	11.50	EPS this Y	21.10%	Inst Trans	0.87%	Short Ratio	7.88	Perf Half Y	-24.32%
Book/sh	1.24	P/B	9.01	EPS next Y	20.60%	ROA	-37.00%	Target Price	18.63	Perf Year	19.85%
Cash/sh	2.01	P/C	5.55	EPS next 5Y	-1.00%	ROE	-75.70%	52W Range	6.25 - 25.39	Perf YTD	-51.62%
Dividend	-	P/FCF	-	EPS past 5Y	-9.90%	ROI	-55.10%	52W High	-56.32%	Beta	1.36
Dividend %	-	Quick Ratio	5.10	Sales past 5Y	172.00%	Gross Margin	88.40%	52W Low	77.44%	ATR	1.03
Employees	584	Current Ratio	5.20	Sales Q/Q	38.10%	Oper. Margin	-	RSI (14)	20.85	Volatility	5.28% 6.05%
Optionable	Yes	Debt/Eq	1.21	EPS Q/Q	-1.80%	Profit Margin	-	Rel Volume	0.58	Prev Close	11.17
Shortable	Yes	LT Debt/Eq	1.21	Earnings	Mar 01 BMO	Payout	-	Avg Volume	3.95M	Price	11.09
Recom	2.40	SMA20	-26.43%	SMA50	-42.69%	SMA200	-34.61%	Volume	143,183	Change	-0.72%

Mar-02-21

Initiated

Stifel

Hold

$13

Feb-12-21

Downgrade

JP Morgan

Overweight → Neutral

$19

Feb-12-21

Downgrade

Cantor Fitzgerald

Overweight → Neutral

$30 → $17

Dec-28-20

Resumed

Cantor Fitzgerald

Overweight

$20 → $30

Dec-10-20

Downgrade

Citigroup

Buy → Neutral

$20 → $27

Nov-11-20

Initiated

Berenberg

Hold

Jun-17-20

Initiated

BTIG Research

Buy

$19

Feb-04-20

Resumed

Cantor Fitzgerald

Overweight

$19 → $20

Nov-12-19

Reiterated

H.C. Wainwright

Buy

$18 → $20

Jun-17-19

Initiated

H.C. Wainwright

Buy

$18

Jun-05-19

Reiterated

Cantor Fitzgerald

Overweight

$20 → $19

Apr-05-19

Initiated

Janney

Buy

Jan-30-19

Initiated

Cantor Fitzgerald

Overweight

$20

Oct-29-18

Initiated

Citigroup

Neutral

$12

Aug-17-18

Downgrade

Chardan Capital Markets

Buy → Neutral

$18 → $15

Oct-06-17

Resumed

Goldman

Neutral

Sep-13-17

Reiterated

Chardan Capital Markets

Buy

$17.50 → $16.50

Aug-10-17

Reiterated

Chardan Capital Markets

Buy

$12.50 → $17.50

Jan-24-17

Upgrade

Robert W. Baird

Neutral → Outperform

$7 → $10

May-18-16

Initiated

BofA/Merrill

Buy

$10

Mar-02-21 12:51PM	Amicus' (FOLD) Q4 Earnings Miss Estimates, Sales Beat on Galafold Zacks -5.26%
01:30AM	Amicus Therapeutics Inc (FOLD) Q4 2020 Earnings Call Transcript Motley Fool
Mar-01-21 08:35AM	Amicus Therapeutics (FOLD) Reports Q4 Loss, Tops Revenue Estimates Zacks
07:24AM	Amicus Therapeutics: Q4 Earnings Insights Benzinga
07:00AM	Amicus Therapeutics Announces Full-Year 2020 Financial Results and Corporate Updates GlobeNewswire
06:30AM	Amicus Therapeutics, Inc. to Host Earnings Call ACCESSWIRE
Feb-26-21 10:10AM	Earnings Preview for Amicus Therapeutics Benzinga
Feb-18-21 07:00AM	Amicus Therapeutics to Present at Upcoming Investor Conferences GlobeNewswire
Feb-17-21 07:00AM	Amicus Therapeutics to Announce Full-Year 2020 Financial Results on March 1, 2021 GlobeNewswire
Feb-12-21 04:22PM	Why This Rare-Disease Biotech Stock Just Lost A Third Of Its Value Investor's Business Daily -32.89%
10:06AM	Benzinga's Top Ratings Upgrades, Downgrades For February 12, 2021 Benzinga
07:55AM	SVB Leerink, J.P. Morgan downgrade Amicus stock after Phase 3 data for rare disease drug comes out MarketWatch
07:19AM	Amicus Reports Disappointing Tests Results for Pompe Disease Drug TheStreet.com
Feb-11-21 04:01PM	Amicus AT-GAA Shows Clinically Meaningful & Significant Improvements in Both Musculoskeletal and Respiratory Measures in Late-Onset Pompe Disease Compared to Standard of Care in Pivotal Phase 3 PROPEL Study GlobeNewswire
Feb-08-21 02:30PM	Amicus Therapeutics Presents Positive Preclinical Fabry Disease Gene Therapy Data at the 17th Annual WORLDSymposium 2021 GlobeNewswire
02:30PM	Amicus Therapeutics Announces Positive Initial Clinical Data for CLN3 Batten Disease Gene Therapy at the 17th Annual WORLDSymposium 2021 GlobeNewswire
Jan-28-21 08:40AM	Implied Volatility Surging for Amicus Therapeutics (FOLD) Stock Options Zacks
Jan-21-21 07:00AM	Amicus Therapeutics Announces Presentations and Posters at the 17th Annual WORLDSymposium 2021 GlobeNewswire
Jan-18-21 02:37AM	If You Had Bought Amicus Therapeutics (NASDAQ:FOLD) Stock Five Years Ago, You Could Pocket A 191% Gain Today Simply Wall St.
Jan-11-21 07:00AM	Amicus Therapeutics Reports Preliminary 2020 Revenue and Provides 2021 Outlook GlobeNewswire
Jan-05-21 07:00AM	Amicus Therapeutics to Present at the 39th Annual J.P. Morgan Healthcare Conference GlobeNewswire
Dec-21-20 11:36AM	Is FOLD A Good Stock To Buy Now? Insider Monkey
Dec-18-20 02:00PM	Sarepta, Amicus Top Biotech Picks Ahead Of Key Binary Events: Analyst Benzinga
Dec-15-20 08:42AM	Amicus Therapeutics (FOLD) Catches Eye: Stock Jumps 8.1% Zacks
Dec-13-20 03:16AM	A Look At The Intrinsic Value Of Amicus Therapeutics, Inc. (NASDAQ:FOLD) Simply Wall St.
Dec-07-20 07:00AM	Amicus Therapeutics Named a Great Place to Work-Certified Company in 2020 GlobeNewswire
Dec-05-20 11:32AM	Why Is Amicus Therapeutics (FOLD) Up 8.6% Since Last Earnings Report? Zacks
Dec-02-20 03:52PM	Amicus (FOLD) Initiates Rolling BLA Submission for AT-GAA Zacks
07:00AM	Amicus Therapeutics Appoints Michael A. Kelly to its Board of Directors GlobeNewswire
Dec-01-20 07:00AM	Amicus Therapeutics Initiates Rolling Biologic License Application to the U.S. Food and Drug Administration for AT-GAA in Late-Onset Pompe Disease GlobeNewswire
Nov-23-20 07:00AM	Amicus Therapeutics to Present at the Evercore ISI 3rd Annual HealthCONx Conference GlobeNewswire
Nov-19-20 09:16AM	Sanofi (SNY) Pompe Disease Drug Gets FDA's Priority Tag Zacks
Nov-07-20 09:29AM	Amicus Therapeutics, Inc. (NASDAQ:FOLD) Just Reported And Analysts Have Been Lifting Their Price Targets Simply Wall St.
Nov-06-20 06:30PM	Amicus Therapeutics Inc (FOLD) Q3 2020 Earnings Call Transcript Motley Fool
10:52AM	Amicus' (FOLD) Q3 Loss Wider Than Expected, Revenues Beat Zacks
Nov-05-20 09:15AM	Amicus Therapeutics (FOLD) Reports Q3 Loss, Tops Revenue Estimates Zacks
07:00AM	Amicus Therapeutics Announces Third Quarter 2020 Financial Results and Corporate Updates GlobeNewswire
06:30AM	Amicus Therapeutics, Inc. to Host Earnings Call ACCESSWIRE
Nov-02-20 07:00AM	Amicus Therapeutics to Present at the Credit Suisse 29th Annual Virtual Healthcare Conference GlobeNewswire
Oct-29-20 12:34PM	Will Amicus Therapeutics (FOLD) Report Negative Earnings Next Week? What You Should Know Zacks
Oct-26-20 07:02AM	Read This Before Selling Amicus Therapeutics, Inc. (NASDAQ:FOLD) Shares Simply Wall St.
Oct-22-20 07:00AM	Amicus Therapeutics to Announce Third Quarter 2020 Financial Results on November 5, 2020 GlobeNewswire
Oct-18-20 08:31AM	3 Monster Growth Stocks That Could Reach New Highs TipRanks
Oct-12-20 08:22AM	4 Breakout Stocks for Explosive Returns Zacks
07:00AM	Amicus Therapeutics Announces Additional Positive Interim Clinical Data for CLN6 Batten Disease Gene Therapy at 49th Annual Meeting of the Child Neurology Society GlobeNewswire
Sep-24-20 07:00AM	Amicus Therapeutics Receives European Medicines Agency PRIME Designation for CLN6 Batten Disease Gene Therapy GlobeNewswire
Sep-15-20 09:07AM	Is Amicus Therapeutics, Inc. (FOLD) Going to Burn These Hedge Funds? Insider Monkey
Sep-09-20 11:30AM	Amicus Therapeutics (FOLD) Down 7.5% Since Last Earnings Report: Can It Rebound? Zacks
Sep-04-20 06:37AM	How Does Amicus Therapeutics' (NASDAQ:FOLD) CEO Pay Compare With Company Performance? Simply Wall St.
Sep-03-20 07:00AM	Amicus Therapeutics to Present at Upcoming Investor Conferences in September 2020 GlobeNewswire -5.05%
Aug-10-20 07:01PM	Amicus Therapeutics Inc (FOLD) Q2 2020 Earnings Call Transcript Motley Fool
08:25AM	Amicus Therapeutics (FOLD) Reports Q2 Loss, Misses Revenue Estimates Zacks
07:27AM	Recap: Amicus Therapeutics Q2 Earnings Benzinga
07:00AM	Amicus Therapeutics Announces Second Quarter 2020 Financial Results and Corporate Updates GlobeNewswire
Aug-04-20 07:00AM	Amicus Therapeutics to Present at the BTIG Virtual Biotechnology Conference GlobeNewswire
Aug-03-20 12:31PM	Will Amicus Therapeutics (FOLD) Report Negative Earnings Next Week? What You Should Know Zacks
Jul-31-20 07:42AM	New Strong Sell Stocks for July 31st Zacks
Jul-28-20 07:00AM	Amicus Therapeutics to Announce Second Quarter 2020 Financial Results on August 10, 2020 GlobeNewswire
Jul-17-20 08:04AM	The Amicus Therapeutics (NASDAQ:FOLD) Share Price Has Gained 16% And Shareholders Are Hoping For More Simply Wall St.
07:32AM	Amicus Therapeutics Secures $400 Million Non-Dilutive Debt Financing GlobeNewswire
Jul-12-20 08:16PM	Did Hedge Funds Make The Right Call On Amicus Therapeutics, Inc. (FOLD)? Insider Monkey
Jun-22-20 09:23AM	Amicus Therapeutics (FOLD) Catches Eye: Stock Jumps 8.9% Zacks
Jun-08-20 03:38AM	Amicus Therapeutics, Inc. (FOLD): Hedge Funds Folding Their Hands Insider Monkey -9.00%
Jun-06-20 11:31AM	Why Is Amicus Therapeutics (FOLD) Up 10.9% Since Last Earnings Report? Zacks
Jun-04-20 07:00AM	Amicus Therapeutics to Present at the Goldman Sachs 41st Annual Global Healthcare Conference GlobeNewswire
May-21-20 02:25PM	Edited Transcript of FOLD earnings conference call or presentation 7-May-20 12:30pm GMT Thomson Reuters StreetEvents
May-19-20 09:47AM	Billionaire Steven Cohen Bets Big on These 3 Stocks TipRanks
May-10-20 09:50AM	Analysts Are Updating Their Amicus Therapeutics, Inc. (NASDAQ:FOLD) Estimates After Its First-Quarter Results Simply Wall St.
May-09-20 01:31PM	Amicus Therapeutics Inc (FOLD) Q1 2020 Earnings Call Transcript Motley Fool
May-08-20 11:46AM	7 Strong Buy Healthcare Stocks to Buy Now InvestorPlace
07:00AM	Amicus Therapeutics Announces Virtual 2020 Annual Meeting of Shareholders GlobeNewswire
May-07-20 09:25AM	Amicus Therapeutics (FOLD) Reports Q1 Loss, Tops Revenue Estimates Zacks
07:00AM	Amicus Therapeutics Announces First Quarter 2020 Financial Results and Corporate Updates GlobeNewswire
May-06-20 07:00AM	UPDATE Amicus Therapeutics Announces Upcoming Presentations at the American Society of Gene & Cell Therapy 23rd Annual Meeting GlobeNewswire
May-05-20 07:00AM	Amicus Therapeutics Announces Upcoming Presentations at the American Society of Gene & Cell Therapy 23rd Annual Meeting GlobeNewswire
Apr-30-20 12:33PM	Will Amicus Therapeutics (FOLD) Report Negative Earnings Next Week? What You Should Know Zacks
Apr-24-20 07:00AM	Amicus Therapeutics to Announce First Quarter 2020 Financial Results on May 7, 2020 GlobeNewswire +6.13%
Apr-13-20 08:42AM	Is Amicus Therapeutics, Inc. (NASDAQ:FOLD) A Volatile Stock? Simply Wall St.
Apr-01-20 11:30AM	Amicus Therapeutics (FOLD) Up 1.1% Since Last Earnings Report: Can It Continue? Zacks
Mar-28-20 08:38PM	Hedge Funds Have Never Been This Bullish On Amicus Therapeutics, Inc. (FOLD) Insider Monkey
Mar-24-20 10:00AM	Edited Transcript of FOLD earnings conference call or presentation 2-Mar-20 1:30pm GMT Thomson Reuters StreetEvents +7.93%
Mar-23-20 07:00AM	Amicus Therapeutics Confirms Business Continuity, 2020 Strategic Priorities and Announces Proactive Efforts to Support Public Health Initiatives, Patients & Employees GlobeNewswire
Mar-05-20 07:00AM	Amicus Opens New Global Research and Gene Therapy Center of Excellence in Philadelphia GlobeNewswire
Mar-04-20 07:20AM	Amicus Therapeutics, Inc. Yearly Results Just Came Out: Here's What Analysts Are Forecasting For Next Year Simply Wall St. +5.91%
Mar-03-20 02:20PM	Amicus set to unveil $25M global research and gene therapy center in University City (Photo gallery) American City Business Journals
09:38AM	Amicus' (FOLD) Q4 Earnings Miss Estimates, Sales Surpass Zacks
Mar-02-20 08:25AM	Amicus Therapeutics (FOLD) Reports Q4 Loss, Tops Revenue Estimates Zacks
07:00AM	Amicus Therapeutics Announces Full-Year 2019 Financial Results and 2020 Corporate Updates GlobeNewswire
Feb-26-20 07:00AM	Amicus Therapeutics to Present at the Cowen & Company 40th Annual Health Care Conference GlobeNewswire
Feb-24-20 12:30PM	Amicus Therapeutics (FOLD) May Report Negative Earnings: Know the Trend Ahead of Next Week's Release Zacks
Feb-19-20 07:00AM	Amicus Therapeutics to Announce Full-Year 2019 Financial Results on March 2, 2020 GlobeNewswire
Feb-17-20 07:43AM	Our Take On Amicus Therapeutics, Inc.'s (NASDAQ:FOLD) CEO Salary Simply Wall St.
Feb-07-20 07:00AM	Amicus Therapeutics Announces Presentations and Posters at 16th Annual WORLDSymposium 2020 GlobeNewswire
Jan-13-20 07:00AM	Amicus Therapeutics Provides Full-Year 2020 Strategic Outlook and Financial Guidance GlobeNewswire -5.66%
Jan-10-20 11:43AM	2019 Review: Most Favored Hedge Fund Stocks vs. Amicus Therapeutics, Inc. (FOLD) Insider Monkey
Jan-09-20 07:00AM	Amicus Therapeutics Announces Preliminary 2019 Galafold Revenue - Exceeding Upper End of Prior Guidance GlobeNewswire
Jan-08-20 10:04AM	Amicus (FOLD) Provides Updates on AT-GAA for Pompe Disease Zacks
Jan-07-20 07:00AM	Amicus Therapeutics Provides Updates on Clinical, Regulatory and Manufacturing Advancements for AT-GAA for Pompe Disease GlobeNewswire
Jan-06-20 06:32PM	Edited Transcript of FOLD earnings conference call or presentation 11-Nov-19 1:30pm GMT Thomson Reuters StreetEvents
Jan-03-20 09:41AM	Amicus Progresses on Pipeline Development Amid Competition Zacks

Amicus Therapeutics, Inc., a biotechnology company, engages in the discovery, development, and commercialization of therapies to treat a range of rare and orphan diseases. The company offers Galafold, an orally administered small molecule pharmacological chaperone for the treatment of Fabry disease. It is also conducting Phase 3 (ATB200-03) clinical study of AT-GAA for Pompe disease. The company has collaboration and license agreements with Nationwide Children's Hospital and University of Pennsylvania. Amicus Therapeutics, Inc. was founded in 2002 and is headquartered in Philadelphia, Pennsylvania.

Insider Trading	Relationship	Date	Transaction	Cost	#Shares	Value ($)	#Shares Total	SEC Form 4
Crowley John F	Chairman & CEO	Feb 22	Sale	11.98	7,682	92,027	844,206	Feb 24 05:07 PM
Crowley John F	Chairman & CEO	Feb 16	Option Exercise	6.45	22,000	141,900	873,888	Feb 18 06:48 PM
Crowley John F	Chairman & CEO	Feb 16	Sale	12.26	22,000	269,700	851,888	Feb 18 06:48 PM
Campbell Bradley L	Chief Operating Officer	Feb 01	Option Exercise	6.45	10,514	67,815	389,371	Feb 03 05:58 PM
WHITMAN BURKE W	Director	Feb 01	Buy	19.09	1,500	28,637	41,467	Feb 03 06:00 PM
Campbell Bradley L	Chief Operating Officer	Feb 01	Sale	19.08	10,514	200,571	378,857	Feb 03 05:58 PM
Crowley John F	Chairman & CEO	Feb 01	Sale	19.08	7,500	143,077	851,888	Feb 03 05:59 PM
Crowley John F	Chairman & CEO	Jan 20	Sale	21.51	50,000	1,075,325	859,388	Jan 20 06:14 PM
Crowley John F	Chairman & CEO	Jan 15	Option Exercise	6.45	22,000	141,900	931,388	Jan 20 06:14 PM
Crowley John F	Chairman & CEO	Jan 15	Sale	22.24	22,000	489,368	909,388	Jan 20 06:14 PM
Campbell Bradley L	Chief Operating Officer	Jan 04	Option Exercise	6.45	10,514	67,815	316,847	Jan 05 07:40 PM
WHITMAN BURKE W	Director	Jan 04	Buy	23.17	1,500	34,755	39,967	Jan 05 07:31 PM
Campbell Bradley L	Chief Operating Officer	Jan 04	Sale	22.17	10,514	233,125	306,333	Jan 05 07:40 PM
Crowley John F	Chairman & CEO	Jan 04	Sale	22.17	7,500	166,305	745,429	Jan 05 08:07 PM
Quimi Daphne	Chief Financial Officer	Dec 21	Option Exercise	2.94	5,000	14,700	249,344	Dec 23 05:45 PM
Quimi Daphne	Chief Financial Officer	Dec 21	Sale	24.09	5,000	120,474	244,344	Dec 23 05:45 PM
Quimi Daphne	Chief Financial Officer	Dec 15	Option Exercise	3.27	30,321	99,222	248,500	Dec 17 04:32 PM
Campbell Bradley L	Chief Operating Officer	Dec 15	Option Exercise	5.45	20,828	113,597	359,592	Dec 17 04:31 PM
Crowley John F	Chairman & CEO	Dec 15	Option Exercise	6.45	22,000	141,900	845,513	Dec 16 05:16 PM
Crowley John F	Chairman & CEO	Dec 15	Sale	23.91	22,000	526,101	823,513	Dec 16 05:16 PM
Do Hung	Chief Science Officer	Dec 14	Sale	23.88	111,125	2,653,276	409,682	Dec 16 05:15 PM
Campbell Bradley L	Chief Operating Officer	Dec 01	Option Exercise	2.52	24,783	62,453	363,547	Dec 02 06:39 PM
WHITMAN BURKE W	Director	Dec 01	Buy	23.50	1,500	35,250	38,467	Dec 03 06:27 PM
Crowley John F	Chairman & CEO	Dec 01	Sale	22.77	7,500	170,777	823,513	Dec 02 06:41 PM
Campbell Bradley L	Chief Operating Officer	Dec 01	Sale	22.77	24,783	564,192	338,764	Dec 02 06:39 PM
Prout Samantha	Principal Accounting Officer	Nov 04	Option Exercise	14.40	5,931	85,378	23,066	Nov 06 05:57 PM
Prout Samantha	Principal Accounting Officer	Nov 04	Sale	20.00	5,931	118,620	17,135	Nov 06 05:57 PM
Campbell Bradley L	Chief Operating Officer	Nov 02	Option Exercise	2.52	24,782	62,451	363,546	Nov 04 07:11 PM
Crowley John F	Chairman & CEO	Nov 02	Option Exercise	5.96	23,975	142,891	864,888	Nov 04 07:24 PM
WHITMAN BURKE W	Director	Nov 02	Buy	18.01	1,500	27,015	36,967	Nov 04 07:25 PM
Crowley John F	Chairman & CEO	Nov 02	Sale	17.87	33,875	605,272	831,013	Nov 04 07:24 PM
Campbell Bradley L	Chief Operating Officer	Nov 02	Sale	17.87	24,782	442,792	338,764	Nov 04 07:11 PM
Do Hung	Chief Science Officer	Oct 09	Option Exercise	10.19	193,700	1,974,507	714,507	Oct 13 05:00 PM
Do Hung	Chief Science Officer	Oct 09	Sale	15.03	193,700	2,911,272	520,807	Oct 13 05:00 PM
Quimi Daphne	Chief Financial Officer	Oct 02	Option Exercise	2.45	11,000	26,950	218,179	Oct 05 05:10 PM
Quimi Daphne	Chief Financial Officer	Oct 01	Option Exercise	2.94	5,000	14,700	212,179	Oct 05 05:10 PM
Crowley John F	Chairman & CEO	Oct 01	Option Exercise	5.96	20,000	119,200	870,813	Oct 05 05:11 PM
WHITMAN BURKE W	Director	Oct 01	Buy	14.28	1,500	21,413	35,467	Oct 05 05:12 PM
Crowley John F	Chairman & CEO	Oct 01	Sale	14.02	29,900	419,105	840,913	Oct 05 05:11 PM
Quimi Daphne	Chief Financial Officer	Oct 01	Sale	14.02	5,000	70,099	207,179	Oct 05 05:10 PM
Barth Jay	Chief Medical Officer	Sep 30	Option Exercise	2.29	4,064	9,307	167,268	Oct 02 04:34 PM
Barth Jay	Chief Medical Officer	Sep 30	Sale	14.51	4,064	58,951	163,204	Oct 02 04:34 PM
Campbell Bradley L	Chief Operating Officer	Sep 28	Option Exercise	2.52	24,782	62,451	363,546	Sep 30 04:38 PM
Campbell Bradley L	Chief Operating Officer	Sep 28	Sale	13.89	24,782	344,205	338,764	Sep 30 04:38 PM
Crowley John F	Chairman & CEO	Sep 01	Option Exercise	5.96	20,000	119,200	880,713	Sep 02 04:28 PM
WHITMAN BURKE W	Director	Sep 01	Buy	14.62	1,500	21,930	33,967	Sep 02 04:28 PM
Crowley John F	Chairman & CEO	Sep 01	Sale	14.18	29,900	423,850	850,813	Sep 02 04:28 PM
Barth Jay	Chief Medical Officer	Aug 31	Option Exercise	6.10	28,750	175,375	191,954	Sep 02 04:27 PM
Barth Jay	Chief Medical Officer	Aug 31	Sale	14.74	28,750	423,746	163,204	Sep 02 04:27 PM
Crowley John F	Chairman & CEO	Aug 17	Option Exercise	5.13	20,000	102,600	880,713	Aug 19 04:56 PM
Crowley John F	Chairman & CEO	Aug 17	Sale	14.89	20,000	297,814	860,713	Aug 19 04:56 PM
Prout Samantha	Principal Accounting Officer	Aug 05	Option Exercise	10.04	198	1,988	17,333	Aug 07 08:04 PM
Prout Samantha	Principal Accounting Officer	Aug 05	Sale	15.05	198	2,980	17,135	Aug 07 08:04 PM
Crowley John F	Chairman & CEO	Aug 03	Option Exercise	5.96	20,000	119,200	900,368	Aug 05 04:02 PM
Campbell Bradley L	Chief Operating Officer	Aug 03	Option Exercise	6.06	10,000	60,600	348,764	Aug 05 04:03 PM
WHITMAN BURKE W	Director	Aug 03	Buy	14.53	1,500	21,795	32,467	Aug 05 04:05 PM
Campbell Bradley L	Chief Operating Officer	Aug 03	Sale	14.78	10,000	147,779	338,764	Aug 05 04:03 PM
Crowley John F	Chairman & CEO	Aug 03	Sale	14.78	39,655	586,081	860,713	Aug 05 04:02 PM
Barth Jay	Chief Medical Officer	Jul 27	Option Exercise	6.10	30,000	183,000	193,204	Jul 29 09:41 PM
Barth Jay	Chief Medical Officer	Jul 27	Sale	15.05	30,000	451,377	163,204	Jul 29 09:41 PM
Rosenberg Ellen	Chief Legal Officer	Jul 16	Option Exercise	5.16	30,000	154,800	225,169	Jul 20 05:31 PM
Rosenberg Ellen	Chief Legal Officer	Jul 16	Sale	15.26	30,000	457,911	195,169	Jul 20 05:31 PM
Crowley John F	Chairman & CEO	Jul 15	Option Exercise	5.13	20,000	102,600	900,368	Jul 17 06:28 PM
Crowley John F	Chairman & CEO	Jul 15	Sale	15.54	20,000	310,848	880,368	Jul 17 06:28 PM
Barth Jay	Chief Medical Officer	Jul 10	Option Exercise	5.13	28,843	147,965	192,047	Jul 13 06:54 PM
Barth Jay	Chief Medical Officer	Jul 10	Sale	15.65	28,843	451,433	163,204	Jul 13 06:54 PM
Barth Jay	Chief Medical Officer	Jul 09	Option Exercise	10.37	44,447	460,867	207,651	Jul 13 06:54 PM
Barth Jay	Chief Medical Officer	Jul 09	Sale	15.92	44,447	707,494	163,204	Jul 13 06:54 PM
Campbell Bradley L	Chief Operating Officer	Jul 08	Option Exercise	6.06	2,500	15,150	341,264	Jul 09 06:47 PM
Barth Jay	Chief Medical Officer	Jul 08	Option Exercise	10.17	64,110	652,165	227,314	Jul 09 06:51 PM
Barth Jay	Chief Medical Officer	Jul 08	Sale	15.92	64,110	1,020,574	163,204	Jul 09 06:51 PM
Campbell Bradley L	Chief Operating Officer	Jul 08	Sale	16.01	2,500	40,025	338,764	Jul 09 06:47 PM
Barth Jay	Chief Medical Officer	Jul 07	Option Exercise	9.89	178,988	1,770,220	342,192	Jul 09 06:51 PM
Barth Jay	Chief Medical Officer	Jul 07	Sale	15.90	178,988	2,845,945	163,204	Jul 09 06:51 PM
Prout Samantha	Principal Accounting Officer	Jul 02	Option Exercise	10.04	198	1,988	1,733	Jul 06 07:50 PM
Prout Samantha	Principal Accounting Officer	Jul 02	Sale	15.80	198	3,128	17,135	Jul 06 07:50 PM
Campbell Bradley L	Chief Operating Officer	Jul 01	Option Exercise	6.06	12,500	75,750	351,264	Jul 06 07:47 PM
Crowley John F	Chairman & CEO	Jul 01	Option Exercise	5.96	20,000	119,200	920,023	Jul 06 07:45 PM
Quimi Daphne	Chief Financial Officer	Jul 01	Option Exercise	2.62	19,872	52,054	214,051	Jul 06 07:38 PM
WHITMAN BURKE W	Director	Jul 01	Buy	15.20	1,500	22,800	30,967	Jul 06 07:38 PM
Campbell Bradley L	Chief Operating Officer	Jul 01	Sale	15.47	12,500	193,384	338,764	Jul 06 07:47 PM
Crowley John F	Chairman & CEO	Jul 01	Sale	15.48	39,655	613,859	880,368	Jul 06 07:45 PM
Quimi Daphne	Chief Financial Officer	Jul 01	Sale	15.47	6,872	106,326	207,179	Jul 06 07:38 PM
Barth Jay	Chief Medical Officer	Jun 29	Option Exercise	5.13	30,000	153,900	193,204	Jul 01 07:00 PM
Barth Jay	Chief Medical Officer	Jun 29	Sale	15.51	30,000	465,195	163,204	Jul 01 07:00 PM
Prout Samantha	Principal Accounting Officer	Jun 19	Option Exercise	10.04	3,366	33,795	20,501	Jun 23 06:47 PM
Prout Samantha	Principal Accounting Officer	Jun 19	Sale	15.00	3,366	50,490	17,135	Jun 23 06:47 PM
Barth Jay	Chief Medical Officer	Jun 17	Sale	13.47	1,904	25,639	163,204	Jun 17 08:33 PM
Prout Samantha	Principal Accounting Officer	Jun 16	Sale	12.95	2,932	37,959	17,135	Jun 17 08:25 PM
Crowley John F	Chairman & CEO	Jun 15	Option Exercise	5.13	20,000	102,600	920,186	Jun 17 08:26 PM
Crowley John F	Chairman & CEO	Jun 15	Sale	10.88	20,000	217,610	900,186	Jun 17 08:26 PM
Campbell Bradley L	Chief Operating Officer	Jun 02	Option Exercise	6.06	2,500	15,150	350,353	Jun 03 09:10 PM
WHITMAN BURKE W	Director	Jun 02	Buy	12.66	2,000	25,311	23,612	Jun 03 09:06 PM
Campbell Bradley L	Chief Operating Officer	Jun 02	Sale	13.01	2,500	32,525	347,853	Jun 03 09:10 PM
RAAB MICHAEL	Director	Jun 01	Option Exercise	2.81	5,000	14,050	20,145	Jun 03 09:09 PM
Campbell Bradley L	Chief Operating Officer	Jun 01	Option Exercise	6.06	10,000	60,600	365,355	Jun 03 09:10 PM
Crowley John F	Chairman & CEO	Jun 01	Sale	12.66	9,755	123,452	900,186	Jun 03 09:14 PM
Campbell Bradley L	Chief Operating Officer	Jun 01	Sale	12.66	17,502	221,495	347,853	Jun 03 09:10 PM
RAAB MICHAEL	Director	Jun 01	Sale	12.65	5,000	63,261	15,145	Jun 03 09:09 PM
Campbell Bradley L	Chief Operating Officer	May 26	Option Exercise	6.06	2,500	15,150	357,855	May 28 05:20 PM

open in yahoo | open in reuters | open in google

Upgrade your FINVIZ experience